Pierre Luc Eymard

This inventor holds 16 USPTO granted patents. Top assignees: Labaz, Sanofi. Active years: 1976-1983.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pierre Luc Eymard. Retrieved from https://idiyas.com/inventor/pierre-luc-eymard

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 16

% Patents Active = 100.0

Average Co-Inventor Count = 3.6

ph-index = 5

Forward Citations = 138(Granted Patents)

Company Filing History:

Years Active: 1976-1983

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 4423071 - Polyol derivatives, processes for preparing the same and their uses in (1983-12-27),

2. 4283420 - Pharmaceutically active cyclohexyl compounds and their preparation (1981-08-11),

3. 4246282 - .omega.-Dialkylalkanoic acid derivatives used to induce antianoxic (1981-01-20),

4. 4223041 - Urea derivatives to treat anxiety and aggressivity (1980-09-16),

5. 4201725 - Secondary amines (1980-05-06),

6. 4139634 - Indole derivatives and process for preparing the same (1979-02-13),

7. 4115401 - Prostaglandin derivatives and process for preparing the same (1978-09-19),

8. 4057644 - Active derivatives of methylamine in therapeutic compositions and (1977-11-08),

9. 4048334 - Active derivatives of methylamino in therapeutic compositions and (1977-09-13),

10. 4032660 - Acetoxime derivatives and process for preparing the same (1977-06-28),

11. 4026925 - Active derivatives of methylamine, therapeutic compositions containing (1977-05-31),

12. 4025649 - Acetic acid derivatives having pharmacological activity and compositions (1977-05-24),

13. 3988472 - Tri-N-propylacetic acid derivatives for therapeutic use (1976-10-26),

14. 3984470 - Amidoxime derivatives and process for preparing the same (1976-10-05),

15. 3958011 - Compositions of tri-n-propylacetic acid and salts thereof and treatment (1976-05-18),

Title: The Innovative Contributions of Pierre Luc Eymard

Introduction

Pierre Luc Eymard is a notable inventor based in Fontaine, France. He has made significant contributions to the field of chemistry, particularly in the development of pharmaceutical compounds. With a total of 16 patents to his name, Eymard's work has had a considerable impact on drug formulation and therapeutic applications.

Latest Patents

Eymard's latest patents include innovative polyol derivatives and processes for their preparation. These compounds are utilized in the creation of mono-, di-, tri-, and tetra-esters derived from specific acids. Notably, he has developed pharmaceutically active cyclohexyl compounds that exhibit anticonvulsant and/or antianoxic activity. The chemical compounds he has invented are characterized by a general formula that includes various functional groups, making them versatile for use in medicinal applications.

Career Highlights

Throughout his career, Pierre Luc Eymard has worked with prominent companies such as Labaz and Sanofi. His experience in these organizations has allowed him to refine his expertise in chemical research and development. Eymard's contributions have not only advanced scientific knowledge but have also led to practical applications in the pharmaceutical industry.

Collaborations

Eymard has collaborated with esteemed colleagues, including Charles Pigerol and Jean-Claude Vernieres. These partnerships have fostered a collaborative environment that has enhanced the innovation process and led to the successful development of new chemical compounds.

Conclusion

Pierre Luc Eymard's work exemplifies the spirit of innovation in the field of chemistry. His patents and collaborations have significantly contributed to advancements in pharmaceutical science, showcasing his dedication to improving health outcomes through innovative solutions.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]